Shield Therapeutics has filed an IND application with the FDA to initiate a Phase III trial of ST10, its novel oral iron-replacement therapy, for the treatment of iron deficiency anaemia (IDA) in pre-dialysis patients with chronic kidney disease (CKD). ST10 is a novel oral ferric iron therapy being developed for the treatment of iron deficiency. It has demonstrated potential as an effective oral alternative to parenteral (IV) iron in ferrous-intolerant patients. Previous clinical studies have s...